NCT01456052 - A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 30, 2012

Primary Completion Date

September 3, 2013

Study Completion Date

September 3, 2013

Conditions

Ulcerative Colitis

Interventions

DRUG

Telotristat Etiprate

500 mg telotristat etiprate (LX1606) administered orally.

DRUG

Placebo

Matching placebo administered orally.

Trial Locations (24)

10017

Lexicon Investigational Site, New York

11021

Lexicon Investigational Site, Great Neck

31531

Lexicon Investigational Site, Krakow

53025

Lexicon Investigational Site, Wroclaw

54144

Lexicon Investigational Site, Wroclaw

72205

Lexicon Investigational Site, Little Rock

74135

Lexicon Investigational Site, Tulsa

77030

Lexicon Investigational Site, Houston

78229

Lexicon Investigational Site, San Antonio

81756

Lexicon Investigational Site, Sopot

84094

Lexicon Investigational Site, Sandy City

84405

Lexicon Investigational Site, Ogden

90302

Lexicon Investigational Site, Lodz

90404

Lexicon Investigational Site, Santa Monica

91501

Lexicon Investigational Site, Nové Mesto nad Váhom

92801

Lexicon Investigational Site, Anaheim

94901

Lexicon Investigational Site, Nitra

98195

Lexicon Investigational Site, Seattle

LT-50009

Lexicon Investigational Site, Kaunas

LT-92288

Lexicon Investigational Site, Klaipėda

LT-76231

Lexicon Investigational Site, Šiauliai

LT-03215

Lexicon Investigational Site, Vilnius

LT-08661

Lexicon Investigational Site, Vilnius

03580

Lexicon Investigational Site, Warsaw